March 3, 2009 - Boston Scientific Corp. today said it launched its TAXUS Liberté Paclitaxel-Eluting Coronary Stent System in Japan.
The product was approved on Jan. 28 by the Ministry of Health, Labor and Welfare, and reimbursement was granted yesterday by the National Health Insurance System.
TAXUS Liberté is the only second-generation drug-eluting stent available in Japan. Design improvements over the company’s first-generation TAXUS Express2 Stent include thinner struts to allow better stent deliverability and conformability, as well as uniform stent geometry for consistent lesion coverage and drug distribution.
Approximately 1,300 medical centers perform cardiac catheterization in Japan. The number of coronary stents implanted annually in the country is estimated at 200,000.
For more information: www.bostonscientific.com